 |
Introducing The Vaso Blog! |
We are excited to announce VasoMedical's brand new blog, where we will provide weekly updates on heart health, EECP® Therapy, industry events and company updates.
Through commentary from members of VasoMedical's executive team and guest bloggers, we hope to create a dialogue not only about heart health, but also about the treatments, such as EECP® Therapy, that are making a difference in patients' lives.
You may already know us, but in case you don't: VasoMedical, Inc. is a diversified medical technology company specializing in the design, manufacture and sale of medical devices and equipment. It operates through its three wholly owned subsidiaries, VasoSolutions, VasoMedical Global, and VasoHealthcare. VasoMedical is the leading ECP (external counterpulsation) therapy manufacturer with its proprietary, patented EECP® Therapy Systems and it currently supports approximately 75 percent of the ECP therapy market. You can read more about the Company and our history here, and learn more about EECP® Therapy here.
Also, make sure to check us out on Facebook, Twitter and LinkedIn for more updates, medical news and technological developments.
We hope you enjoy the blog! Go To The Vaso Blog Now!
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly-owned subsidiaries. VasoMedical Solutions manages and coordinates the design, manufacture and sales of EECP® therapy systems, its core product, as well as other medical equipment operations; VasoMedical Global operates the Company’s China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.